Related Experiment Video
Updated: Apr 25, 2026

Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
Anti-diabetic formulations of Nāga bhasma (lead calx): A brief review
Dhirajsingh Rajput1, B J Patgiri1, R Galib1
1Department of Rasashastra sand Bhaishajya Kalpana, I.P.G.T. and R.A., Gujarat Ayurved University, Jamnagar, Gujarat, India.
Introduction:
Ayurvedic formulations usually contain ingredients of herbal, mineral, metal or animal in origin. Nāga bhasma (lead calx) is a potent metallic formulation mainly indicated in the treatment of Prameha (~diabetes). Until date, no published information is available in compiled form on the formulations containing Nāga bhasma as an ingredient, their dose and indications. Therefore, in the present study, an attempt has been made to compile various formulations of Nāga bhasma indicated in treating Prameha.
Aim:
The present work aims to collect information on various formulations of Nāga bhasma mainly indicated in treating Prameha and to elaborate the safety and efficacy of Nāga bhasma as a Pramehaghna (antidiabetic) drug.
Materials And Methods:
Critical review of formulations of Nāga bhasma is compiled from various Ayurvedic texts and the therapeutic efficacy of Nāga bhasma is discussed on the basis of available data.
Result And Conclusion:
Antidiabetic formulations of Nāga bhasma were discovered around 12(th) century CE. There are 44 formulations of Nāga bhasma mainly indicated for Prameha. Haridrā (Curcuma longa Linn), Āmalakī (Emblica officinalis), Guḍūci (Tinospora cordifolia) and Madhu (honey) enhance the antidiabetic action of Nāga bhasma and also help to prevent diabetic complications as well as any untoward effects of Nāga bhasma. On the basis of the reviewed research, it is concluded that Nāga bhasma possesses significant antidiabetic property.
Related Concept Videos
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Sulfonylureas
